Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10A INSULINS AND ANALOGUES
A10AE Insulins and analogues for injection, long-acting
A10AE54 Insulin glargine and lixisenatide
D11034 Insulin glargine and lixisenatide <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Combinations
Insulin Glargine/ Lixisenatide
D11034 Insulin glargine and lixisenatide
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D11034 Insulin glargine and lixisenatide
Drug groups [BR:br08330]
Antidiabetic agent
DG01636 Insulin preparation
DG03229 Combination of insulin analog and GLP-1 receptor agonist
D11034 Insulin glargine and lixisenatide
Drug classes [BR:br08332]
Antidiabetic agent
DG01636 Insulin preparation
D11034 Insulin glargine and lixisenatide
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP1R
D11034 Insulin glargine and lixisenatide <JP/US>
Protein kinases
Receptor tyrosine kinases (RTK)
INSR family
INSR (CD220)
D11034 Insulin glargine and lixisenatide <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11034
